Position in LGND
as of Mar 31, 2026
· filed Apr 27, 2026
Position Value
$3,854,442
New position
Shares Held
19,306
first reported quarter
Ownership
0.096%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Moran Wealth Management, LLC holds $27,467,675 across 10 Biotechnology names. LGND ranks #3 (14.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
175,822 | $8,434,180 | |
| 2 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
168,961 | $4,183,474 | |
| 3 | LGND |
Ligand Pharmaceuticals Inc
This page
|
19,306 | $3,854,442 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,398 | $3,398,070 | |
| 5 | EXEL |
Exelixis, Inc.
|
63,905 | $2,740,885 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
30,477 | $1,969,728 | |
| 7 | STOK |
Stoke Therapeutics, Inc.
|
40,552 | $1,320,373 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
25,302 | $1,203,616 |
All Filings in LGND
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,854,442 | 19,306 | Shares | Sole | 2026-04-27 | |
| No filing history on record for this holder in this stock. | ||||||